SynthesisEndocrine2026
Adrenal schwannomas and adrenal ganglioneuromas: our experience and CT characteristic-focused systematic review.
Synthesis in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe accuracy of computed tomography (CT) parameters in the preoperative diagnosis of benign adrenal lesions, such as adrenal schwannoma (AS) and adrenal ganglioneuroma (AG), has not been systematically studied. Hence, we aimed to analyze CT features of AS/AG to distinguish them from other lipid-poor, poor-washout adrenal masses.
methodsDescription of our AS/AG cohort, along with systematic review of literature for histopathologically confirmed AS/AG and available CT characteristics (providing unenhanced, early venous, and delayed venous phase attenuation). These were compared with our previously published cohort of other lipid-poor, poor-washout adrenal masses (n = 47).
resultsThe cohort included AS (n = 30; literature:25, our center:5), AG (n = 27; literature:25, our center:2). AS and AG were similar, except AG patients were younger (28 vs. 49.5 years, p = 0.003). All AS and 92.5% of AG were nonsecretory. Progressive delayed enhancement (PDE) [relative percentage washout (RPW) < 0%] occurred in all AS and 70.4% of AG. Compared to other masses, AS were more often nonsecretory (100% vs. 68.1%, p < 0.001), cystic (71.4% vs. 10.6%, p < 0.001), calcified (52.6% vs. 10.6%, p = 0.001), and had lower RPW (-19.7% vs. 24.3%, p < 0.001). RPW achieved highest AUC (1.000), with 100% sensitivity and specificity at -1.5%. Similarly, AG were younger (28 vs. 42 years, p = 0.022), more often nonsecretory (92.5% vs. 68.1%, p = 0.020), and had lower RPW (-36.3% vs. 24.3%, p < 0.001; AUC:0.923) with 100% specificity and 70.4% sensitivity at -3.4%.
conclusionPDE in a lipid-poor, poor-washout adrenal mass is specific for AS and AG and makes other common etiologies unlikely. External validation is required before widespread clinical integration.
Indexed as
Identifiers
41563553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.